Antigenic evolution of SARS coronavirus 2

IF 5.7 2区 医学 Q1 VIROLOGY
Anna Z Mykytyn, Ron AM Fouchier, Bart L Haagmans
{"title":"Antigenic evolution of SARS coronavirus 2","authors":"Anna Z Mykytyn,&nbsp;Ron AM Fouchier,&nbsp;Bart L Haagmans","doi":"10.1016/j.coviro.2023.101349","DOIUrl":null,"url":null,"abstract":"<div><p>SARS coronavirus 2 (SARS-CoV-2), the causative agent of COVID-19, emerged in China in December 2019. Vaccines developed were very effective initially, however, the virus has shown remarkable evolution with multiple variants spreading globally over the last three years. Nowadays, newly emerging Omicron lineages are gaining substitutions at a fast rate, resulting in escape from neutralization by antibodies that target the Spike protein. Tools to map the impact of substitutions on the further antigenic evolution of SARS-CoV-2, such as antigenic cartography, may be helpful to update SARS-CoV-2 vaccines. In this review, we focus on the antigenic evolution of SARS-CoV-2, highlighting the impact of Spike protein substitutions individually and in combination on immune escape.</p></div>","PeriodicalId":11082,"journal":{"name":"Current opinion in virology","volume":"62 ","pages":"Article 101349"},"PeriodicalIF":5.7000,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current opinion in virology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1879625723000494","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"VIROLOGY","Score":null,"Total":0}
引用次数: 1

Abstract

SARS coronavirus 2 (SARS-CoV-2), the causative agent of COVID-19, emerged in China in December 2019. Vaccines developed were very effective initially, however, the virus has shown remarkable evolution with multiple variants spreading globally over the last three years. Nowadays, newly emerging Omicron lineages are gaining substitutions at a fast rate, resulting in escape from neutralization by antibodies that target the Spike protein. Tools to map the impact of substitutions on the further antigenic evolution of SARS-CoV-2, such as antigenic cartography, may be helpful to update SARS-CoV-2 vaccines. In this review, we focus on the antigenic evolution of SARS-CoV-2, highlighting the impact of Spike protein substitutions individually and in combination on immune escape.

SARS冠状病毒的抗原进化
2019年12月,新冠肺炎病原体SARS冠状病毒2(SARS-CoV-2)在中国出现。开发的疫苗最初非常有效,然而,该病毒在过去三年中表现出了显著的进化,多种变体在全球传播。如今,新出现的奥密克戎谱系正在以快速的速度获得取代,导致其无法被靶向刺突蛋白的抗体中和。绘制替代对严重急性呼吸系统综合征冠状病毒2型进一步抗原进化影响的工具,如抗原图谱,可能有助于更新严重急性呼吸系冠状病毒2型疫苗。在这篇综述中,我们重点关注严重急性呼吸系统综合征冠状病毒2型的抗原进化,强调刺突蛋白取代单独和联合对免疫逃逸的影响。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
11.80
自引率
5.10%
发文量
76
审稿时长
83 days
期刊介绍: Current Opinion in Virology (COVIRO) is a systematic review journal that aims to provide specialists with a unique and educational platform to keep up to date with the expanding volume of information published in the field of virology. It publishes 6 issues per year covering the following 11 sections, each of which is reviewed once a year: Emerging viruses: interspecies transmission; Viral immunology; Viral pathogenesis; Preventive and therapeutic vaccines; Antiviral strategies; Virus structure and expression; Animal models for viral diseases; Engineering for viral resistance; Viruses and cancer; Virus vector interactions. There is also a section that changes every year to reflect hot topics in the field.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信